Adele Fielding

Adele Fielding, MB BChir, PhD, FRCPath is Professor of Haematology at University College London and Chair of the UKALL Steering Group, the leading UK cooperative group for adult ALL research. She is one of the UK's most prominent hematologists specializing in adult ALL and has led a series of pivotal UKALL clinical trials that have shaped adult ALL treatment in the United Kingdom and internationally. Dr. Fielding led UKALL14, a landmark phase III trial incorporating rituximab into frontline adult B-ALL therapy for CD20-positive patients, demonstrating significant improvement in MRD negativity rates and event-free survival. She has been a key investigator in European studies evaluating blinatumomab in adult ALL, both as a MRD-directed consolidation agent and in the newly diagnosed frontline setting, including trials designed to assess its integration into pediatric-inspired chemotherapy backbones in young and middle-aged adults. Her expertise in T-ALL has led to important studies examining the role of nelarabine in newly diagnosed T-ALL and the emerging use of venetoclax in combination regimens for this subtype. Dr. Fielding is also highly regarded for her translational research on BCL2 family proteins as therapeutic targets in ALL and her work on T-ALL oncogenesis, particularly the biology of NOTCH1-mutated T-ALL and its clinical implications.